中国肝脏病杂志(电子版)

位置：首页 >> 期刊文章

恩替卡韦联合六味五灵片治疗乙型肝炎肝硬化患者疗效分析

作者：于莉丁体龙涂远航李珊珊马勇

单位：解放军第一二三医院南京军区肝病中心

关键词：肝炎乙型肝硬化恩替卡韦六味五灵片

分类号：

出版年,卷(期):页码：2015,7(1):63-65

摘要：

摘要：目的探讨恩替卡韦（ETV）联合六味五灵片治疗乙型肝炎肝硬化的疗效。方法将122例乙型肝炎肝硬化患者随机分为对照组60例（口服ETV 0.5 mg/日）和治疗组62例（口服ETV 0.5 mg/日），同时给予六味五灵片1.5 g/次，每日3次口服，疗程均为24周。治疗结束后观察肝功能、HBV DNA低于检测下限的比率、HA、LN、PC-Ⅲ、CIV水平。结果 24周观察结束时治疗组的肝功能、HBV DNA低于检测下限的比率以及HA、LN、PC-Ⅲ、CIV指标下降情况均优于对照组，差异有统计学意义（P ＜ 0.01）。结论 ETV联合六味五灵片治疗乙型肝炎肝硬化疗效显著，疗效优于单一用药组，是治疗乙型肝炎肝硬化的有效方法。

Abstract: Objective To observe the clinical effect of entecavir (ETV) combined with Liuweiwuling tablets on hepatic cirrhosis. Methods Total of 122 hepatic cirrhosis patients were randomly divided into treatment group and control group: the control group (60 cases) were treated with ETV (0.5 mg/d) for 24 weeks; while the treatment group (62 cases) were treated with Liuweiwuling tablets (1.5 g once, three times a day) and ETV (0.5 mg/d) for 24 weeks. The liver function, HBV DNA and liver fibrosis markers (HA, LN, PC-Ⅲ, CIV) between the two groups were compared after treatment. Results The liver function, HBV DNA and liver fibrosis markers (HA, LN, PC-Ⅲ, CIV) in the treatment group were better than those in the control group (P < 0.01). Conclusions ETV combined with Liuweiwuling tablet therapy is an effective treatment and more effective than that with ETV only for patients with hepatic cirrhosis.

基金项目：

作者简介：

参考文献：

服务与反馈：

【文章下载】【加入收藏】